Nevertheless, recent studies indicated heterogeneity in terms of PD-L1 expression levels in the extracranial NSCLC and brain metastases, resulting in a potentially inaccurate stratification of patients to checkpoint inhibitor immunotherapy [13, 14, 15, 16]. Here, CD274 is linked to non-small cell lung carcinoma.